A Case of Improved Refractory Uveitis in Behcet's Disease after Infliximab Therapy.
- Author:
Jeong Woo CHOI
1
;
Yong Joon CHOI
;
Young Min YE
;
Sang Ha KIM
;
Dong Ho NAM
;
Hae Sim PARK
;
Ma Bin LEE
;
Ho Min YOO
;
Chang Hee SUH
Author Information
1. Department of Allergy-Rheumatology, Ajou University School of Medicine, Suwon, Korea. chsuh@ajou.ac.kr
- Publication Type:Case Report
- Keywords:
Behcet's disease;
Uveitis;
TNFalpha;
Anti-TNFalpha treatment
- MeSH:
Arthritis;
Blindness;
Cytokines;
Humans;
Korea;
T-Lymphocytes;
Thrombophlebitis;
Tumor Necrosis Factor-alpha;
Uveitis*;
Vasculitis;
Infliximab
- From:The Journal of the Korean Rheumatism Association
2005;12(4):320-323
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Behcet's disease is a multisystemic, chronic relapsing inflammatory disease characterized by vasculitides, mucocutaneous lesions, thrombophlebitis, arthritis. Among them, the ocular involvement is usual (50~70%) and the most serious morbidity is blindness (20~25% of those of affected). Immunosuppressive treatment is currently the main therapy in chronic relapsing uveitis, but many patients experience recurrent sight-threatening uveitis. T lymphocytes play an important role in the pathogenesis of uveitis by releasing cytokines such as tumor necrosis factor (TNF) alpha. There are some reports that the anti-TNFalpha treatment is effective in refractory Behcet's uveitis, but it has not been reported in Korea. We report a case of refractory uveitis in Behcet's disease which is improved after anti-TNFalpha therapy.
